## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -7.8% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($323.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Is Cencora (COR) Quietly Rewriting Its Moat With an Aggressive Bet on Cryogenic Logistics?**
- Source: Simply Wall Street | 20251205T033505 | Somewhat-Bullish | Relevance: 100%
- Cencora is strategically expanding its third-party logistics, particularly in ultra-low and cryogenic storage, to become a deeper partner for complex therapies like cell and gene treatments. This aggressive investment aims to bolster their cold chain and specialty storage capacity, potentially reshaping the company's investment narrative and risk profile. Investors are evaluating whether these new specialty logistics capabilities can support margins without unduly burdening the balance sheet, especially given current debt and valuation.

**2. Why Cencora (COR) Shares Are Trading Lower Today**
- Source: Finviz | 20251203T152600 | Somewhat-Bearish | Relevance: 100%
- Cencora (COR) shares fell 4.3% after analysts downgraded the stock to a "hold" from a "buy," contributing to a negative trend. Despite this, the stock has shown significant gains year-to-date and over the past five years. The market considered the downgrade meaningful, though it may not fundamentally alter the perception of the business, especially considering the stock's low volatility.

**3. JPMorgan Raises Cencora (COR) Price Target After Financial Model Update**
- Source: Insider Monkey | 20251203T145900 | Bullish | Relevance: 100%
- JPMorgan increased its price target for Cencora (NYSE: COR) to $417 from $344 while maintaining an Overweight rating, following an update to the company's financial model. Cencora announced plans to invest $1 billion through 2030 to strengthen its US supply chain and reported Q4 FY25 results that surpassed expectations, with revenue of $83.7 billion. The company also raised its quarterly dividend by 9% to $0.60 per share and projected adjusted operating income growth of 6% to 9% and adjusted EPS growth of 9% to 13%.

**4. Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities**
- Source: Markets Financial Content | 20251203T123000 | Bullish | Relevance: 100%
- Cencora is investing to expand its third-party logistics (3PL) and cold chain capabilities in both the United States and Europe. This expansion includes acquiring NextPharma Logistics, opening a new 3PL facility in Italy by 2026, and a 500,000 square-foot facility in Texas by 2028 to support the growing demand for specialty pharmaceuticals and cell and gene therapies. These enhancements aim to provide comprehensive and integrated supply chain solutions for pharmaceutical companies globally.

**5. How Is Cencoraâ€™s Stock Performance Compared to Other Medical Stocks?**
- Source: Markets Financial Content | 20251203T083500 | Bullish | Relevance: 100%
- Cencora, Inc. (COR) is a leading global pharmaceutical-services company with a market cap of $58.7 billion. Its stock has outperformed the Health Care Select Sector SPDR Fund (XLV) over the past three months, YTD, and the last 52 weeks. Analysts have a "Strong Buy" rating on COR with a mean price target suggesting a 10.5% upside.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | JP Morgan | $417 | $344 | +21% |
| 2025-11-11 | Wells Fargo | $405 | $354 | +14% |
| 2025-11-10 | TD Cowen | $400 | $350 | +14% |
| 2025-11-07 | UBS | $415 | $380 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | JP Morgan | main | Overweight |
| 2025-11-11 | Wells Fargo | main | Overweight |
| 2025-11-10 | TD Cowen | main | Buy |
| 2025-11-07 | UBS | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +14%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.81 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Analyst sentiment positive (6 raises, avg +14%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $66.2B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.81 |
| Forward P/E | 17.4 |
| Current P/E | 19.4 |
| YoY Growth | 11.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.5% to -7.8% (-6.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.8pp (needs >4.0% for momentum thesis). AM_20 at -5.7% indicates price below own 20MA trend. Underperforming sector by 5.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.14x) but short-term weakness (below SMA20). MACD histogram bearish (-5.15), momentum weakening. RSI neutral at 40. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.85% (CS: 3) | Weak |
| RSI_14 | 40.3 | Neutral |
| MACD Histogram | -5.15 | Bearish |
| vs SMA20 | 0.943x | Below |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 1.138x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $339.66
- **Stop Loss:** $323.88 (4.6% risk)
- **Target:** $355.44 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $10,529.46
- **Portfolio %:** 10.53%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*